Safety and efficacy of gefitinib for treatment of advanced non-small cell lung cancer / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 66-69, 2007.
Article
in Chinese
| WPRIM
| ID: wpr-255721
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the safety and efficacy of gefitinib as second-line or even third-line treatment for previously treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).</p><p><b>METHODS</b>156 patients with locally advanced NSCLC which were about to undergo progression after previous chemotherapy were eligible for this study. The regimen was oral intake of gefitinib 250 mg once daily in the morning or afternoon until the disease progression or toxicity has become intolerable. The drug was provided by AstroZeneca Company by its Expanded Access Program.</p><p><b>RESULTS</b>154 such patients were evaluable for response and toxicity assessment. The overall rate of objective response and disease control was 28.6% (44/154) and 89.6% (138/154). The median duration of response was 7. 5 months. The median time to disease progression (TTP) was 5. 1 months and the median overall survival time (OS) 10.0 months. The actuarial 1-year survival was 41. 0%. The response rate in adenocarcinoma was significantly higher than that in squamous carcinoma (P = 0. 026). The risk of disease progression in patients with squamous carcinoma was 1. 7 times as much as that of adenocarcinoma patients ( P = 0. 011) , and the risk of death in male was 2. 0 times as much as that in female ( P = 0. 002). At least one of these adverse events would be observed in 40.9% (63/154) of these patients, which, however was mild and reversible. Conclusion Gefitinib is effective and safe as a second-line or third-line treatment for previously treated patients with locally advanced or metastatic non-small cell lung cancer.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pathology
/
Quinazolines
/
Remission Induction
/
Carcinoma, Squamous Cell
/
Adenocarcinoma
/
Sex Factors
/
Treatment Outcome
/
Carcinoma, Non-Small-Cell Lung
/
Disease Progression
/
Therapeutic Uses
Limits:
Aged
/
Female
/
Humans
/
Male
Language:
Chinese
Journal:
Chinese Journal of Oncology
Year:
2007
Type:
Article
Similar
MEDLINE
...
LILACS
LIS